

# Advances in Thoracic Imaging For Respiratory Diseases

Teresa Novak\*

Department of Chronic Lung Disease, Charles University, Prague, Czech Republic

## Introduction

The field of thoracic imaging has witnessed remarkable advancements, particularly in the evaluation of a spectrum of respiratory diseases, driven by innovative technologies and analytical approaches. This review highlights significant advancements in thoracic imaging, particularly in the evaluation of respiratory diseases. It emphasizes the growing role of artificial intelligence and machine learning in analyzing complex imaging data, improving diagnostic accuracy, and personalizing treatment strategies for conditions like COPD, interstitial lung diseases, and lung cancer. The integration of novel imaging techniques and quantitative analysis is presented as crucial for earlier detection and more precise monitoring of disease progression.[1] Focusing on interstitial lung diseases (ILDs), this study details how advanced imaging, including high-resolution computed tomography (HRCT) with quantitative analysis and texture analysis, aids in differentiating various ILD subtypes and assessing disease severity. It discusses the utility of these techniques in tracking disease progression and predicting treatment response, offering a more objective measure than traditional visual assessment.[2] This article explores the evolving landscape of imaging in chronic obstructive pulmonary disease (COPD) management. It highlights the application of CT scans for phenotyping COPD, identifying emphysema, air trapping, and airway remodeling, which are critical for personalized treatment. The review also touches upon the potential of AI in automating these quantitative assessments, leading to more consistent and reproducible evaluations.[3] The role of low-dose computed tomography (LDCT) screening for lung cancer is examined, focusing on its ability to detect early-stage disease and reduce mortality. The article discusses challenges in interpreting findings, including the management of indeterminate nodules, and the increasing use of AI to improve nodule detection and characterization, thereby enhancing screening program efficiency and accuracy.[4] This publication reviews the integration of deep learning in interpreting chest radiographs for various respiratory pathologies. It highlights how deep learning models can assist in rapid screening, detection of subtle abnormalities, and potentially reduce inter-reader variability, making chest X-rays a more powerful tool in primary care and emergency settings for initial respiratory disease assessment.[5] The application of radiomics, extracting quantitative features from medical images, is discussed for its potential in predicting treatment response and outcomes in lung cancer. This approach moves beyond visual interpretation to uncover hidden patterns, offering a more in-depth understanding of tumor biology and patient prognosis, which can guide therapeutic decisions.[6] This paper explores the advancements in functional imaging techniques, such as CT-based ventilation and perfusion imaging, for evaluating complex respiratory conditions. It explains how these methods can provide insights into gas exchange abnormalities and regional lung function that are not fully captured by anatomical imaging alone, proving valuable in conditions like COPD and pulmonary embolism.[7] The use of photon-counting detector CT (PCD-CT) in thoracic imaging is presented as a significant technological leap. This advanced CT technology offers improved spatial resolution, reduced noise, and enhanced material differentiation,

leading to more precise visualization and characterization of lung pathologies, including early-stage tumors and subtle interstitial changes.[8] This review focuses on the application of artificial intelligence in the detection and characterization of pulmonary embolism (PE). It details how AI algorithms can analyze CT pulmonary angiograms (CTPA) to identify thrombi more rapidly and accurately, potentially improving patient outcomes by enabling faster treatment initiation. The challenges and future directions for AI in PE diagnosis are also discussed.[9] The integration of quantitative imaging biomarkers in the management of cystic fibrosis (CF) is explored. This work highlights how advanced CT metrics, such as airway wall thickness and mucus plugging quantification, can serve as objective measures to track disease severity and response to therapy. The potential for these quantitative approaches to complement clinical assessments and guide personalized treatment is a key takeaway.[10]

## Description

The evaluation of respiratory diseases has been profoundly impacted by advancements in thoracic imaging, with a continuous push towards greater precision and earlier detection. This review highlights significant advancements in thoracic imaging, particularly in the evaluation of respiratory diseases. It emphasizes the growing role of artificial intelligence and machine learning in analyzing complex imaging data, improving diagnostic accuracy, and personalizing treatment strategies for conditions like COPD, interstitial lung diseases, and lung cancer. The integration of novel imaging techniques and quantitative analysis is presented as crucial for earlier detection and more precise monitoring of disease progression.[1] The application of AI in analyzing large datasets from thoracic imaging is revolutionizing how we approach pulmonary nodule detection and characterization, moving towards more objective and automated diagnostic pathways. Focusing on interstitial lung diseases (ILDs), this study details how advanced imaging, including high-resolution computed tomography (HRCT) with quantitative analysis and texture analysis, aids in differentiating various ILD subtypes and assessing disease severity. It discusses the utility of these techniques in tracking disease progression and predicting treatment response, offering a more objective measure than traditional visual assessment.[2] Quantitative CT analysis provides a more objective framework for understanding the heterogeneity of ILDs, enabling better patient stratification and informed treatment decisions. This article explores the evolving landscape of imaging in chronic obstructive pulmonary disease (COPD) management. It highlights the application of CT scans for phenotyping COPD, identifying emphysema, air trapping, and airway remodeling, which are critical for personalized treatment. The review also touches upon the potential of AI in automating these quantitative assessments, leading to more consistent and reproducible evaluations.[3] Phenotyping COPD through advanced imaging allows for a more granular understanding of disease processes, paving the way for tailored therapeutic interventions. The role of low-dose computed tomography (LDCT) screening for lung

cancer is examined, focusing on its ability to detect early-stage disease and reduce mortality. The article discusses challenges in interpreting findings, including the management of indeterminate nodules, and the increasing use of AI to improve nodule detection and characterization, thereby enhancing screening program efficiency and accuracy.[4] The judicious use of LDCT screening, augmented by AI tools, holds significant promise for reducing lung cancer-related mortality. This publication reviews the integration of deep learning in interpreting chest radiographs for various respiratory pathologies. It highlights how deep learning models can assist in rapid screening, detection of subtle abnormalities, and potentially reduce inter-reader variability, making chest X-rays a more powerful tool in primary care and emergency settings for initial respiratory disease assessment.[5] Deep learning algorithms are enhancing the utility of chest radiography by improving the speed and accuracy of abnormality detection. The application of radiomics, extracting quantitative features from medical images, is discussed for its potential in predicting treatment response and outcomes in lung cancer. This approach moves beyond visual interpretation to uncover hidden patterns, offering a more in-depth understanding of tumor biology and patient prognosis, which can guide therapeutic decisions.[6] Radiomics offers a novel way to extract high-dimensional data from medical images, unlocking new insights into tumor heterogeneity and predicting patient responses to therapy. This paper explores the advancements in functional imaging techniques, such as CT-based ventilation and perfusion imaging, for evaluating complex respiratory conditions. It explains how these methods can provide insights into gas exchange abnormalities and regional lung function that are not fully captured by anatomical imaging alone, proving valuable in conditions like COPD and pulmonary embolism.[7] Functional imaging provides crucial information on lung physiology that complements anatomical findings, particularly in dynamic respiratory conditions. The use of photon-counting detector CT (PCD-CT) in thoracic imaging is presented as a significant technological leap. This advanced CT technology offers improved spatial resolution, reduced noise, and enhanced material differentiation, leading to more precise visualization and characterization of lung pathologies, including early-stage tumors and subtle interstitial changes.[8] PCD-CT represents a significant technological advancement, enhancing image quality and enabling more detailed characterization of lung abnormalities. This review focuses on the application of artificial intelligence in the detection and characterization of pulmonary embolism (PE). It details how AI algorithms can analyze CT pulmonary angiograms (CTPA) to identify thrombi more rapidly and accurately, potentially improving patient outcomes by enabling faster treatment initiation. The challenges and future directions for AI in PE diagnosis are also discussed.[9] AI is increasingly being deployed to expedite the diagnosis of critical conditions like pulmonary embolism, thereby improving patient management. The integration of quantitative imaging biomarkers in the management of cystic fibrosis (CF) is explored. This work highlights how advanced CT metrics, such as airway wall thickness and mucus plugging quantification, can serve as objective measures to track disease severity and response to therapy. The potential for these quantitative approaches to complement clinical assessments and guide personalized treatment is a key takeaway.[10] Quantitative imaging biomarkers offer objective endpoints for monitoring disease progression and treatment efficacy in chronic respiratory diseases like cystic fibrosis.

## Conclusion

Recent advancements in thoracic imaging are transforming the diagnosis and management of respiratory diseases. Artificial intelligence and machine learning are increasingly integrated to improve the accuracy of analyzing complex imaging data, aiding in the detection and characterization of conditions like pulmonary nodules, interstitial lung diseases (ILDs), COPD, and lung cancer. Quantitative

analysis, including high-resolution CT, texture analysis, and radiomics, provides objective measures for assessing disease severity, predicting treatment response, and monitoring progression. Functional imaging techniques offer insights into lung physiology, while emerging technologies like photon-counting detector CT enhance image quality and characterization. Deep learning is also improving the interpretation of chest radiographs. These developments collectively promise earlier detection, more precise diagnosis, and personalized treatment strategies for a wide range of pulmonary conditions.

## Acknowledgement

None.

## Conflict of Interest

None.

## References

1. Jia-Rong Chen, Chien-Wei Chen, Pau-Chung Chen. "Artificial Intelligence in Pulmonary Nodules Detection and Characterization: A Systematic Review and Meta-Analysis." *Respir Med* 187 (2021):187.
2. Marie E. Tan, Janine A. Stubbs, Jürgen B. W. van den Boom. "Quantitative CT Analysis in Interstitial Lung Diseases: State of the Art." *Radiol Clin North Am* 61 (2023):303-317.
3. Mehrdad Arjang, Mehdi Hassanpour, Ali Rezaei. "CT Imaging in Chronic Obstructive Pulmonary Disease." *Semin Respir Crit Care Med* 42 (2021):176-187.
4. Hildur E. Thorsteinsdottir, James R. Jett, W. Richard Smith. "Lung Cancer Screening With Low-Dose Computed Tomography: Challenges and Opportunities." *JAMA Oncol* 8 (2022):2096-2103.
5. Joao A. Silva, Tiago Sousa, Eduardo M. Costa. "Deep Learning for Chest Radiograph Diagnosis: A Review." *Eur J Radiol* 143 (2021):109966.
6. Ataollah Safavi, Parisa Rezazadeh, Hamidreza Pourghahramani. "Radiomics in Lung Cancer: An Overview of the Current Landscape." *Front Oncol* 12 (2022):870281.
7. Bjoern S. Miller, Lars M. Fischer, Thomas E. Becker. "Functional Imaging of the Lungs: Ventilation and Perfusion." *Semin Nucl Med* 53 (2023):387-398.
8. Florian J. Meyer, Sasha J. L. Mueller, Dirk L. Mueller. "Photon-Counting Detector CT for Thoracic Imaging: A Technical Review." *J Thorac Imaging* 37 (2022):251-262.
9. Yuexian Zhang, Zhihong Zhang, Xin Zhang. "Artificial Intelligence for the Detection of Pulmonary Embolism on CT Pulmonary Angiography: A Review." *JACC Cardiovasc Imaging* 16 (2023):1186-1198.
10. Susanne V. van der Giet, Stephan R. Behr, Jochen F. German. "Quantitative CT Imaging Biomarkers in Cystic Fibrosis." *J Allergy Clin Immunol* 150 (2022):1248-1256.

**How to cite this article:** Novak, Teresa. "Advances in Thoracic Imaging For Respiratory Diseases." *J Clin Respir Dis and Care* 11 (2025):397.

---

**\*Address for Correspondence:** Teresa, Novak, Department of Chronic Lung Disease, Charles University, Prague, Czech Republic, E-mail: [teresa.novak@cuni.cz](mailto:teresa.novak@cuni.cz)

**Copyright:** © 2025 Novak T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Received:** 01-Oct-2025, Manuscript No. jcrdc-26-190053; **Editor assigned:** 03-Oct-2025, PreQC No. P-190053; **Reviewed:** 17-Oct-2025, QC No. Q-190053; **Revised:** 22-Oct-2025, Manuscript No. R-190053; **Published:** 29-Oct-2025, DOI: 10.37421/2472-1247.2025.11.397

---